Project Grant R43HL142395

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $604,750 to Scientific Horizons Consulting LLC to develop and evaluate a novel inhalation device for the pulmonary delivery of anti-inflammatory agents to manage pain in chronic obstructive pulmonary disease (COPD). The device utilizes a novel "bottom-up" aerosolization technology to generate optimized aerosol particles for deep...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will support the development of a bioadhesive vaginal film that provides extended release delivery of contraceptive and antiviral monoclonal antibodies. The total funding amount is $518,754, with an award date of February 1, 2025 and a completion date of January 31, 2026. The project aims to create a versatile,...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award provides $1,198,807 to Nasus Medical, Inc. to develop a novel, self-administered nasal drug delivery device. The project aims to enhance intranasal drug delivery to improve treatment outcomes for chronic sinusitis, a condition affecting 10% of the U.S. population and costing $8-12 billion annually in direct healthcare costs. The proposed technology consists of a...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,530 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Scientific Horizons Consulting LLC located in Irvine, CA. The goal of this one-year grant is to develop a novel antibiotic delivery system using cyclodextrin-based metal-organic frameworks (CD-MOFs) to improve the treatment of non-tuberculous mycobacterial (NTM) lung infections. The key innovations include high antibiotic...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $591,842 to Rebel Medicine Inc., a biotechnology company in Salt Lake City, Utah, to develop an extended-duration, injectable local anesthetic formulation that can reduce the need for opioid medications after surgery. The project aims to demonstrate the safety and efficacy of a proprietary oleogel-based delivery system that can provide up...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support the development of a novel liquid methadone dispensing device and smart container system by Sano Healthcare Consultants, LLC. The $319,000 award will enable the construction of a low-cost, volumetric-controlled liquid methadone dispensing system, with a reusable external smart container that provides remote supervised use, telehealth,...

The U.S. Food and Drug Administration (FDA) awarded a $598,728 cooperative agreement under the FDA Research program (CFDA 93.103) to the University of Texas at Austin to develop physiologically-based pharmacokinetic (PBPK) modeling-based in vitro-in vivo correlations (IVIVC) for poly(lactic-co-glycolic acid) (PLGA) implants. The project aims to (1) establish a bio-predictive in vitro release testing method and determine how formulation and physicochemical properties impact the in vitro release...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a self-administered microneedle patch for the long-acting release of antiretroviral agents. The primary goals are to: 1) formulate and optimize the extended release of the antiretroviral drug islatravir (EFDA) from biodegradable microneedle patches for at least one month, and 2) determine the in vivo...

This $11,811,988 Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of the novel mu-opioid receptor antagonist methocinnamox (MCAM) for preventing relapse and overdose in individuals with opioid use disorder. The award will fund the following key activities over 3 years starting August 15, 2024: submitting an Investigational New Drug (IND) application for MCAM to prevent relapse,...

This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $299,993 to Cmtx Biotech Inc. to develop their lead drug candidate, Incyclinide (CMT-3/COL-3), as a medical countermeasure for the treatment of sulfur mustard-induced lung injury. The project aims to demonstrate a dose-dependent survival benefit of Incyclinide and evaluate its ability to mitigate lung injury, pulmonary fibrosis, and...